Phan Nguyen Thanh Van1
1 Pham Ngoc Thach University of Medicine

Nội dung chính của bài viết

Tóm tắt

Objectives: To analyze the relationship between prognostic factors to outcomes of
number of multiple myeloma (MM) treatment regimens at Ho Chi Minh city (HCMC)
Blood Transfusion and Hematology Hospital from 2018 to 2021.
Subjects and methods: A descriptive and analytical study on 111 patients newly
diagnosed with MM from January 2018 to December 2021 according to IMWG 2014
standards who came for examination and treatment at HCMC Blood Transfusion and
Hematology Hospital.
Results: The prognostic factors associated with statistical significance to the rate of
at least very good partial response (VGPR) compared with the other group including:
Clinical index ECOG < 2, NLR < 2.25, platelet ≥ 150, novel treatment regimen and
myeloma prognostic index (MPI).
Conclusion: Clinical index ECOG < 2, NLR < 2.25, platelet ≥ 150, new treatment
regimen and MPI were the prognostic factors associated with MM.

Chi tiết bài viết

Tài liệu tham khảo

[1] O. Landgren. R. A. Kyle. R. M. Pfeiffer.
et al., Monoclonal gammopathy of
undetermined significance (MGUS)
consistently precedes multiple myeloma:
a prospective study. Blood. 113(22):
5412-7, 2009.
[2] D. A. Goldstein, Denosumab for bone
lesions in multiple myeloma - what is
its value? Haematologica. 103(5): 753-
754, 2018.
[3] N. Tandon. S. Sidana, Outcomes with
early response to first-line treatment in
patients with newly diagnosed multiple
myeloma3(5): 744-750, 2019.
[4] N. J. Bahlis. A. Corso. L. O. Mugge.
et al., Benefit of continuous treatment
for responders with newly diagnosed
multiple myeloma in the randomized
FIRST trial. Leukemia. 31(11): 2435-
2442, 2017.
[5] Y. Li. H. Li. W. Li. et al., Pretreatment
neutrophil/lymphocyte ratio but not
platelet/lymphocyte ratio has a prognostic
impact in multiple myeloma. J Clin Lab
Anal. 31(5), 2017.
[6] A. J. Templeton. M. G. McNamara.
B. Seruga et al., Prognostic role of
neutrophil-to-lymphocyte ratio in solid
tumors: a systematic review and metaanalysis. J Natl Cancer Inst. 106(6):
dju124, 2014.
[7] M. Bakeer. A. C. Zubair. V. Roy, Low
baseline platelet count predicts poor
response to plerixafor in patients with
multiple myeloma undergoing autologous
stem cell mobilization. Cytotherapy.
22(1): 16-20, 2020.
[8] Nguyen Thuy Duong, Study clinical
features. Subclinical and treatment
results in multiple light chain myeloma
at the National Institute of Hematology
and Blood Transfusion. Master thesis in
medicine, 2018.
[9] J. F. San Miguel. R. Schlag. N. K.
Khuageva et al., Bortezomib plus
melphalan and prednisone for initial
treatment of multiple myeloma. N Engl J
Med. 359(9): 906-17, 2008.